drugset
drugset / Trial / NCT00333411

Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis

NCT00333411 ↗

Phase 2 Completed 360 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical study is to determine the effectiveness, pharmacokinetics and safety of several doses of BIRT 2584 XX (100mg, 300mg and 500mg) taken once daily in the treatment of moderate to severe plaque-type psoriasis. This new medicine will be compared to a so-called placebo medicine over 12 weeks with a 12 weeks treatment extension possible.

Timeline

Start
2006-06
Primary completion
2008-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIRT 2584 XX Unknown 100 mg Oral
Subject BIRT 2584 XX Unknown 300 mg Oral
Subject BIRT 2584 XX Unknown 500 mg Oral

Indications

psoriasis